Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Lymphoid 1Gastrointestinal 1Dermatologic 1

Conditions

Multiple Myeloma 5Recurrence 2Lymphoma 2Pancreatic Neoplasms 1Neoplasms, Plasma Cell 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, B-Cell, Marginal Zone 1Leukemia 1Carcinoma, Non-Small-Cell Lung 1

Interventions

fludarabine 3Cyclophosphamide 3Specimen Handling 2Magnetic Resonance Spectroscopy 2zimberelimab 1ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1temsirolimus 1sapanisertib 1resiquimod 1relatlimab 1poly ICLC 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1marizomib 1larotrectinib 1ipatasertib 1interferon-alfa-1b 1erdafitinib 1defactinib 1dabrafenib 1copanlisib 1cobimetinib 1cc-486 1capivasertib 1binimetinib 1adavosertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × marizomib × Plasma cell × Clear all
NCT00667082 2017-11-22

NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma

Celgene

Phase 1 Completed
22 enrolled
DermatologicGastrointestinalLymphoidPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Lymphoma, Melanoma, Multiple Myeloma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡